TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
August 02, 2023 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
July 11, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
June 20, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing Double-Digit Objective Response Rate (ORR) by Blinded...
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
June 16, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...
TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma
June 15, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, June 15, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...
TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
May 30, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023
May 03, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...